Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 9Small Cell Lung Carcinoma 7Biliary Tract Neoplasms 7Carcinoma, Hepatocellular 6Urinary Bladder Neoplasms 4Liver Neoplasms 4Carcinoma 4Neoplasm Metastasis 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma Extensive Disease 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Non-Muscle Invasive Bladder Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Urothelial Cancer 1Sarcoma 1Radiation Pneumonitis 1Pancoast Syndrome 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Non Small Cell Lung Carcinoma NSCLC 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1

Interventions

durvalumab 1Injections 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Biliary Tract Cancer × durvalumab × Clear all
NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
604 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡